Q-omics provides the consensus-scored NCDN profile across patient tissues and cancer cell-line models. NCDN expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, NCDN is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, NCDN protein abundance shows 27,735 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, HNSC, and GBM as cancer lineages where NCDN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCDN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCDN survival associations across molecular data types. NCDN RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCDN RNA expression–survival associations across cancer types. High NCDN expression shows unfavorable associations in SKCM, LIHC, KICH, LUSC, KIRC and BLCA. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for NCDN RNA expression.
This table summarizes NCDN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for NCDN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCDN shows higher tumor expression in HNSC, COAD, LIHC, STAD, BRCA and LUAD. The HNSC box plot shows higher NCDN RNA expression in tumor versus normal tissue (log2 FC = +1.469, t-test p < 0.001).
This table shows molecular features associated with NCDN in patient tissues and cancer cell lines. In patient samples, NCDN shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NCDN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
